All News
EULAR 2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
Babies! Safety and Outcomes Data on Pregnancies
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years.
Read Article
SLE trials update
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases, with many theoretically well-founded agents appearing to have failed in clinical trials as a result of inefficacy, problem with trial design and/or safety issues.
Read Article
Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA
Links:
Richard Conway RichardPAConway ( View Tweet)
#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Schett et al. CAR-T in SLE, case series 4 patients. Effective in inducing clinical remission in all 4 refractory patients. Looks like #rheummadness may have been (almost) correct @DavidLeverenz ! @RheumNow #EULAR2022 OP0279 https://t.co/frAU8COFs8
Links:
Richard Conway RichardPAConway ( View Tweet)
More data on #iberdomide… from phase 2 study --looks like it helps #SCLE and #CCLE (but not for #ACLE) Dr. V Werth #EULAR2022 @rheumnow https://t.co/FYZlB219lf
TheDaoIndex KDAO2011 ( View Tweet)
Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb
TheDaoIndex KDAO2011 ( View Tweet)
#PEARLS by Dr. Werth:
1. anti-malarials only work 50% of time for cutaneous lupus (CLE).
2. AZP is not as effective as MTX or MMF for #CLE
3. Consider RTX refractory #bullous lupus #EULAR2022 @rheumnow https://t.co/6FPJEGWioJ
TheDaoIndex KDAO2011 ( View Tweet)
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
David Liew drdavidliew ( View Tweet)
#PEARLS by EULAR President Prof Iagnocco:
1. Enthesitis can be present in 25% of #SLE patients
2. Erosions can be common and independent of ACPA/RF status
3. Active myositis is indistinguishable from IIM
4. Don't forget pain osteonecrosis/osteomyelitis #EULAR2022 @rheumnow https://t.co/8uWCw9rEve
TheDaoIndex KDAO2011 ( View Tweet)
Staggering facts by Prof Vital on #SLE and SkM Sx’s:
- 50% of first Sx’s is SkM
- SkM Sx are in top 3 concerns for pts
- 34% pts w/SkM Sx stopped working median 4 yrs
- SkM damage clusters with CVD damage
#EULAR2022 @rheumnow https://t.co/NXEW3XYCQZ
TheDaoIndex KDAO2011 ( View Tweet)
“#SLEDAI should be scored when there is joint swelling (not just tenderness)—note that only 48% of pts with tenderness will have u/s evidence of inflammation” – Prof E Vital #EULAR2022 @rheumnow https://t.co/hhsZ9wMAWs
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Werth shared her evidence based algorithm for managing cutaneous lupus published here: https://t.co/RytrxLdLHK #EULAR2022 @rheumnow https://t.co/wq28btM24U
TheDaoIndex KDAO2011 ( View Tweet)
OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF
TheDaoIndex KDAO2011 ( View Tweet)
OP0280 WIN-lupus study eval if #SLE LN pts in remission can stop Rx. In pts who continued vs. stopped Rx: renal relapse 12% vs. 27%, p=0.08 and severe SLE flare 12 vs 32%, p=0.03; pts relapsing had inc baseline UPCR/SLEDAI score; +APS; lower lymphs/C3 . #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 https://t.co/yMJcMAFSh6
Dr. John Cush RheumNow ( View Tweet)
Promising! Prof Schett presents the 1st 5 #SLE pts who received CAR T cell therapy - all went into sustained remission off of meds: new B cells reconstituted at 100 days but SLE did not. OP0279 #EULAR2022 @rheumnow https://t.co/o3Ehp55C4Q
TheDaoIndex KDAO2011 ( View Tweet)
OP0285 Voclosoporin effective in #lupusNephritis from AURA-LV and AURORA1 to achieve EULAR/ERA nephritis targets (proteinuria < 0.7 mg/mg and pred < 7.5 mg/d) at 1 year @AuriniaPharma #EULAR2022 @rheumnow https://t.co/0GoCgP98F2
TheDaoIndex KDAO2011 ( View Tweet)
In a rush for a quick update on selected trial results in #lupus presented at #EULAR2022? Please find my article https://t.co/0XTkPRr6kQ @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
